Brief: Silo Pharma Announces Positive Study Results Of Spu- 21 For Arthritis
30/12/2022 15:16
Dec 30 (Reuters) - Silo Pharma Inc SILO.O :
* SILO PHARMA ANNOUNCES POSITIVE STUDY RESULTS OF SPU- 21
FOR
ARTHRITIS
* SILO PHARMA INC - SPU-21 EFFECTIVE IN CONTROLLING
ARTHRITIS
PROGRESSION
* SILO PHARMA INC - SPU-21 DEMONSTRATES POSITIVE DATA IN
ARTHRITIS
SUPPRESSION USING SILO'S NOVEL JOINT HOMING PEPTIDE
Source text for Eikon: ID:nGNX4LYM08
Further company coverage: SILO.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement